- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: compound 7 [PMID: 26709102] | Gemtesa® | KRP-114V  | MK-4618 | MK4618
vibegron is an approved drug (FDA (2020))
Compound class: Synthetic organic
Comment: Vibegron (MK-4618) is a potent and selective β3 adrenoceptor agonist that was developed by Merck as a pharmacological modulator for the management of overactive bladder [1-2].
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|The efficacy of vibegron (MK-4618) in humans was evaluated in Phase 3 clinical trials in patients with overactive bladder (OAB; see NCT03583372 and NCT03492281). In both of these studies vibegron was directly compared to tolterodine tartrate which is a non-selective murcarinic receptor antagonist that is used to manage urinary incontinence.
In December 2020, the FDA approved vibegron as a once-daily therapeutic for OAB.
|Mechanism Of Action and Pharmacodynamic Effects|
|In vivo (in monkeys), vibegron increases bladder capacity, decreases micturition pressure, and increases bladder compliance |
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT03492281||A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)||Phase 3 Interventional||Urovant Sciences GmbH|
|NCT03583372||An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).||Phase 3 Interventional||Urovant Sciences GmbH|